This Phase II study investigates the combination of Nivolumab, a PD-1 inhibitor, and Bevacizumab, an angiogenesis inhibitor, in patients with recurrent glioblastoma (GBM). The market for glioblastoma treatments is significant, with a high unmet need for effective therapies due to the aggressive nature of the disease and poor prognosis. The combination therapy aims to enhance anti-tumor activity by leveraging immune modulation and vascular normalization. Competitive implications include potential differentiation from existing therapies, particularly in biomarker-driven patient selection. Diligence considerations should focus on the safety profile, efficacy data, and the potential for subsequent regulatory approvals based on the outcomes of this trial.